Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma - Wikidata - wikimedia - TriplyDB

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

http://www.wikidata.org/entity/Q26767435

about

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

P2860

Q36304907-2517B323-6999-4703-87AF-497D1FE60FA0

P2860

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

http://www.wikidata.org/entity/Q26767435

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@ast

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@en

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@nl

type

label

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@ast

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@en

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@nl

prefLabel

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@ast

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@en

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@nl

P1433

Q26767435-3CCE217C-837B-423A-B4C7-5DD12C6F3D23

P1476

Q26767435-7CC6EA15-D742-46D8-8A48-1302E5BC4E6B

P2093

Q26767435-79762607-BE03-43C9-8D2B-23C98EDD0F10

Q26767435-B75A420F-EF6B-4193-A801-77B22A363922

P2860

Q26767435-074EF627-1C0C-49AC-BF80-8B3FC106975B

Q26767435-09406CDB-E23C-4170-8910-495566EE2D1D

Q26767435-10A0E33D-78CC-4795-8674-797AA37CE1DB

Q26767435-1152407B-ACB0-4282-B0B4-604066079B9A

Q26767435-130EEF39-82D0-433D-A4AB-CE9BF1811C7B

Q26767435-1AE002D7-957A-4A8C-8F32-EBE54FBF6F27

Q26767435-1B9F65CA-EF7F-4B21-B70C-A4F216D5CD0E

Q26767435-2484DDDF-3852-4B2D-8959-0D0FE7864963

Q26767435-2865D705-8036-48C4-A476-7101F5A88166

Q26767435-2DADCD24-078F-4B53-951B-F9A7FED9B099

P304

Q26767435-AC998DD6-752D-4158-8FC3-FCEF6820985B

P31

Q26767435-30533F26-5A3D-43A9-838E-09D5F967CC68

P356

Q26767435-2E7250F4-6EF8-498E-8BCD-383B23874D65

P407

Q26767435-340CF1F4-C69F-4DFA-947A-8BCB09C53F39

P433

Q26767435-D2837842-9859-45B8-B823-D973881A5D89

P478

Q26767435-AAB2CFAD-C247-4930-9CEC-D5922F53DFDF

P50

Q26767435-A0D7D43F-D143-41D7-851B-C141B8676D88

P577

Q26767435-D79F03A4-5ECD-4B35-A458-2CC64C7D0C19

P5875

Q26767435-7D738CB5-5506-4B35-8473-664FCE7C50B7

P698

Q26767435-3CF9C999-A345-4D2F-B83E-9C7745B192BE

P921

Q26767435-CDB38773-BE17-4227-AD45-364C75ADD923

P932

Q26767435-0491C42C-4CD0-448F-92C2-0785F5A259E8

P356

P1433

Journal of clinical medicine research

P1476

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

@en

P2093

Khush Mittal

http://www.w3.org/2001/XMLSchema#string

Shabnam Momtahen

http://www.w3.org/2001/XMLSchema#string

P2860

Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

The MYCN oncoprotein as a drug development target.

Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.

Array comparative genomic hybridization analysis of uterine leiomyosarcoma.

Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

P304

181-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/JOCMR2419W

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

292189785

http://www.w3.org/2001/XMLSchema#string

P698

26858789

http://www.w3.org/2001/XMLSchema#string

P921

P932

4737027

http://www.w3.org/2001/XMLSchema#string